API | lucatumumab

lucatumumab Report issue

Biologics mAb Experimental

AACT ChEMBL

Active Ingredient History

NOW

Lucatumumab is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
lucatumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Tumor necrosis factor receptor superfamily member 5 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

chir-12.12 | hcd122 | hcd-122 | lucatumumab

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Hodgkin Disease (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Multiple Myeloma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue